Protease inhibitors are a source of nephrolithiasis in HIV + patients, and these stones are described as not detected by CT. While urinary stones are commonly associated with certain protease inhibitors, stones composed of ritonavir are rare.
To describe the current state of workforce diversity in Female Pelvic Medicine and Reconstructive Surgery (FPMRS) using the 2014-2019 American Urological Association (AUA) census data. We evaluated FPMRS workforce diversity using the AUA census data from 2014 to 2019.
Nowadays, kidney transplantation (KT) is considered the best treatment option for patients with end-stage renal disease, with more than 20,000 KTs being performed each year in Europe. Given the epidemiological relevance and the clinical importance of chronic renal failure disease and KT, as well as, the fundamental role of the urologist in this field, a […]
(UroToday.com) The first session of the Advanced Prostate Cancer Consensus Conference 2021 which was hosted virtually in the context of the COVID-19 pandemic focused on the management of patients with newly diagnosed metastatic hormone-sensitive prostate cancer. In this context, Dr. Claire Vale discussed analytic issues including the role of meta-analysis, network meta-analysis, and subgroup analyses to […]
(UroToday.com) The Advanced Prostate Cancer Consensus Conference 2021 virtual meeting session discussing PARP inhibitors and beyond included a presentation by Dr. Johann De Bono regarding differences between DNA repair defect aberrations and the impact on patient management. Dr. De Bono started by highlighting that >20-30% of advanced prostate cancer patients have DNA repair defect mutations, including […]
(UroToday.com) The Advanced Prostate Cancer Consensus Conference 2021 virtual meeting session discussing PSMA in diagnostics and therapy included a presentation by Dr. Eleni Efstathiou discussing the contagious enthusiasm of PSMA-driven therapeutics. Dr. Efstathiou notes that the VISION study outcomes1 have set the bar high, with 177Lu-PSMA-617 targeted radioligand therapy improving overall survival (OS), radiographic PFS, and […]
(UroToday.com) The Advanced Prostate Cancer Consensus Conference 2021 virtual meeting session discussing PARP inhibitors and beyond included a presentation by Dr. Dana Rathkopf regarding who needs germline testing and what should be tested. There are several groups of patients that need germline testing, according to Dr. Rathkopf:
(UroToday.com) In this session, Dr. Dana Rathkopf discusses germline testing recommendations for men with prostate cancer. Guidelines agree that all men with metastatic prostate cancer should undergo germline testing and recommendations are evolving across the rest of the disease spectrum. New in 2021, the NCCN guidelines recommended germline testing for men with high and very high […]
(UroToday.com) The third and final session of the Advanced Prostate Cancer Consensus Conference 2021 which was hosted virtually in the context of the COVID-19 pandemic focused on molecular characterization of both tissue and blood, with a focus on implications for treatment with PARP inhibitors and beyond. In this context, Dr. Andrew Armstrong discussed considerations regarding tumor […]
(UroToday.com) The third and final session of the Advanced Prostate Cancer Consensus Conference 2021 which was hosted virtually in the context of the COVID-19 pandemic focused on molecular characterization of both tissue and blood, with a focus on implications for treatment with PARP inhibitors and beyond. In the final talk of this session, Dr. Eric Small […]
